E
Endostart
On demand accessory for standard colonoscopes developed to facilitate loop solving and colonoscopy completion
About Endostart
Endostart, founded in 2018, specializes in the development and manufacturing of next-generation medical devices for gastrointestinal endoscopy. The company's flagship product, the Endorail System, is an accessory for colonoscopes designed to facilitate their progression in the large intestine. This system employs Magnetic Balloon Anchoring Technology to enhance the performance of endoscopes, enabling endoscopists to achieve higher quality standards with ease.
Endostart serves healthcare providers and medical professionals in the gastrointestinal endoscopy market. The business model is centered around the sale of its proprietary medical devices, generating revenue through direct sales and partnerships with healthcare institutions. The company has implemented a comprehensive quality management system and achieved ISO 13485 certification in 2020, ensuring high standards in its product offerings.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Certaldo, Italy
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 73.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Gastroenterology, Medical Systems, Endoscopy, Digestion, Hard Tech, Seal of Excellence EC, ogr torino
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | May 2022 | $0 | — | Kairos Partners | ↗ |
| SERIES B✓Equity / VC | Jun 2021 | $9M | $36M | Panakès Partners · Eureka! Venture · LIFTT · HTH | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin | Profit | Margin |
|---|---|---|---|---|---|---|
| 2026 | ||||||
| 2025 | ||||||
| 2024 | ||||||
| 2023 | — | |||||
| 2022 | — | — | — | — | ||
| 2021 | — | — | — | — | ||
| 2020 | — | — | — | — |
Growth signals
Latest recorded traffic for Endostart is 120 monthly website visits, up 500% over the last three months. Endostart's team grew 5.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Panakès Partners
A11 Venture
Series A3 investors entered at this stage
HTH
Eureka! Venture
LIFTT
Series B and later1 investor entered at this stage
Kairos Partners
Other known investors1 additional known investor
MITO Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Endostart on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Endostart’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.